ATRA
Price
$9.23
Change
+$0.81 (+9.62%)
Updated
Jun 6 closing price
Capitalization
55.02M
CLSD
Price
$0.79
Change
+$0.02 (+2.60%)
Updated
Jun 6 closing price
Capitalization
61.12M
70 days until earnings call
Interact to see
Advertisement

ATRA vs CLSD

Header iconATRA vs CLSD Comparison
Open Charts ATRA vs CLSDBanner chart's image
Atara Biotherapeutics
Price$9.23
Change+$0.81 (+9.62%)
Volume$93.31K
Capitalization55.02M
Clearside Biomedical
Price$0.79
Change+$0.02 (+2.60%)
Volume$226.42K
Capitalization61.12M
ATRA vs CLSD Comparison Chart
Loading...
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATRA vs. CLSD commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Buy and CLSD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (ATRA: $7.80 vs. CLSD: $0.79)
Brand notoriety: ATRA and CLSD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 86% vs. CLSD: 197%
Market capitalization -- ATRA: $50.55M vs. CLSD: $61.12M
ATRA [@Biotechnology] is valued at $50.55M. CLSD’s [@Biotechnology] market capitalization is $61.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileCLSD’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • CLSD’s FA Score: 0 green, 5 red.
According to our system of comparison, ATRA is a better buy in the long-term than CLSD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 8 TA indicator(s) are bullish while CLSD’s TA Score has 4 bullish TA indicator(s).

  • ATRA’s TA Score: 8 bullish, 2 bearish.
  • CLSD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ATRA is a better buy in the short-term than CLSD.

Price Growth

ATRA (@Biotechnology) experienced а +12.97% price change this week, while CLSD (@Biotechnology) price change was -6.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

CLSD is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLSD($61.1M) has a higher market cap than ATRA($55M). CLSD YTD gains are higher at: -17.200 vs. ATRA (-41.435). CLSD has higher annual earnings (EBITDA): -22.23M vs. ATRA (-75.75M). ATRA has more cash in the bank: 42.5M vs. CLSD (23.6M). CLSD has less debt than ATRA: CLSD (785K) vs ATRA (43.8M). ATRA has higher revenues than CLSD: ATRA (129M) vs CLSD (7.7M).
ATRACLSDATRA / CLSD
Capitalization55M61.1M90%
EBITDA-75.75M-22.23M341%
Gain YTD-41.435-17.200241%
P/E RatioN/AN/A-
Revenue129M7.7M1,675%
Total Cash42.5M23.6M180%
Total Debt43.8M785K5,580%
FUNDAMENTALS RATINGS
ATRA vs CLSD: Fundamental Ratings
ATRA
CLSD
OUTLOOK RATING
1..100
1913
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3480
P/E GROWTH RATING
1..100
10077
SEASONALITY SCORE
1..100
9585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATRA's Valuation (75) in the Biotechnology industry is in the same range as CLSD (90) in the Pharmaceuticals Major industry. This means that ATRA’s stock grew similarly to CLSD’s over the last 12 months.

ATRA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that ATRA’s stock grew similarly to CLSD’s over the last 12 months.

ATRA's SMR Rating (100) in the Biotechnology industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that ATRA’s stock grew similarly to CLSD’s over the last 12 months.

ATRA's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for CLSD (80) in the Pharmaceuticals Major industry. This means that ATRA’s stock grew somewhat faster than CLSD’s over the last 12 months.

CLSD's P/E Growth Rating (77) in the Pharmaceuticals Major industry is in the same range as ATRA (100) in the Biotechnology industry. This means that CLSD’s stock grew similarly to ATRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRACLSD
RSI
ODDS (%)
Bearish Trend 12 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 12 days ago
85%
Bullish Trend 12 days ago
80%
Momentum
ODDS (%)
Bullish Trend 12 days ago
80%
Bearish Trend 12 days ago
90%
MACD
ODDS (%)
Bullish Trend 12 days ago
87%
Bearish Trend 12 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
82%
Bearish Trend 12 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
80%
Bearish Trend 12 days ago
86%
Advances
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 21 days ago
82%
Declines
ODDS (%)
Bearish Trend 28 days ago
87%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 12 days ago
90%
Bullish Trend 12 days ago
75%
Aroon
ODDS (%)
Bullish Trend 12 days ago
72%
Bullish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with AMLX. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
+4.07%
AMLX - ATRA
65%
Loosely correlated
+1.48%
GRI - ATRA
40%
Loosely correlated
+3.05%
SLRX - ATRA
39%
Loosely correlated
-4.17%
NTLA - ATRA
36%
Loosely correlated
+3.59%
FULC - ATRA
35%
Loosely correlated
+8.66%
More

CLSD and

Correlation & Price change

A.I.dvisor tells us that CLSD and ACLX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLSD and ACLX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLSD
1D Price
Change %
CLSD100%
-4.04%
ACLX - CLSD
28%
Poorly correlated
-1.29%
INBX - CLSD
28%
Poorly correlated
-1.68%
ATRA - CLSD
27%
Poorly correlated
+4.07%
JAZZ - CLSD
26%
Poorly correlated
-2.24%
IKNA - CLSD
26%
Poorly correlated
-2.13%
More